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A B S T R A C T
Background
Venous thromboembolism (VTE) often complicates the clinical course of cancer disease. The risk is further increased by chemotherapy
but the safety and efficacy of primary thromboprophylaxis in cancer patients treated with chemotherapy is uncertain.
Objectives
To assess the efficacy and safety of primary thromboprophylaxis in ambulatory cancer patients receiving chemotherapy.
Search methods
The Cochrane Peripheral Vascular Diseases Group searched their Specialised Register (last searched 3 May 2011) and CENTRAL
(2011, Issue 2). The authors searched clinical trials registries and reference lists of relevant studies.
Selection criteria
Randomised controlled trials (RCTs) comparing unfractionated heparin (UFH), low molecular weight heparin (LMWH), vitamin K
antagonists (VKA), direct thrombin inhibitors, direct factor Xa inhibitors or mechanical intervention to no intervention or placebo;
or comparing two different anticoagulants.
Data collection and analysis
Data were extracted on methodological quality, patients, interventions and outcomes including symptomatic VTE and major bleeding
as the primary effectiveness and safety outcomes, respectively.
Main results
Nine RCTs with a total of 3538 patients were considered. None of the RCTs tested UFH, fondaparinux, direct factor Xa inhibitors
or mechanical interventions. Overall, the risk of bias was low in most of the studies. LMWH, when compared with inactive control,
significantly reduced the incidence of symptomatic VTE (risk ratio (RR) 0.62, 95% confidence interval (CI) 0.41 to 0.93) with no
evidence of heterogeneity (I2 = 0%). The number needed to treat to prevent a symptomatic VTE was 60. LMWHwas associated with a
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60% increase in major bleeding when compared with inactive control, although this was not statistically significant (RR 1.57, 95% CI
0.69 to 3.60; I2 = 10%). There was a 45% reduction in overall VTE (RR 0.55, 95% CI 0.34 to 0.88; I2 = 0%) while for symptomatic
pulmonary embolism, asymptomatic VTE, minor bleeding and one-year mortality the differences between the LMWH and control
groups were not statistically significant. The effect of the vitamin K antagonist warfarin on preventing symptomatic VTE, measured in
only one study, was not statistically significant (RR 0.15, 95% CI 0.02 to 1.20). In one RCT of patients with myeloma, LMWH was
associated with a 67% reduction in symptomatic VTE (RR 0.33, 95% CI 0.14 to 0.83) compared with warfarin, with no differences
in major bleeding. Antithrombin, evaluated in one study on paediatric patients, had no significant effect on VTE nor major bleeding
when compared with inactive control.
Authors’ conclusions
Primary thromboprophylaxis with LMWH significantly reduced the incidence of symptomatic VTE in ambulatory cancer patients
treated with chemotherapy. However, the lack of power hampers definite conclusions on the effects on major safety outcomes, which
mandates additional studies to determine the risk to benefit ratio of LMWH in this setting.
P L A I N L A N G U A G E S U M M A R Y
Protective treatment against blood clots in non-hospitalised cancer patients receiving chemotherapy
Cancer patients are more likely than patients without cancer to develop blood clots in their veins (venous thromboembolism), either
in the lungs (pulmonary embolism) or the deep venous system (deep vein thrombosis or DVT). Chemotherapy further increases this
risk. Yet bleeding at the site of the cancer and a relative decrease in number of platelets in the blood (thrombocytopenia) caused by the
chemotherapy maymake cancer patients more likely to have bleeding complications with blood thinning agents. This systematic review
looked at the effectiveness and safety of blood thinning agents (anticoagulants) when used to prevent blood clots in cancer patients
receiving chemotherapy. Nine randomised controlled studies with a total of 3538 patients investigated the prevention of blood clots
in patients without a history of blood clots. The use of low molecular weight heparin was associated with a reduction in blood clots
(the number needed-to-treat to prevent a symptomatic blood clot was 60) without any clear benefit in survival as the number of major
bleeding events was increased, although this was not statistically significant and further study is needed. The findings from two studies
of the vitamin K antagonist warfarin, one comparing warfarin with low molecular weight heparin in patients with myeloma, were too
limited to support a beneficial effect of warfarin in the prevention of blood clots in cancer patients. Antithrombin was evaluated in one
study in children and had no significant effect on blood clots or major bleeding when compared with an inactive control.
Overall the studies had a low risk of bias but the small number of studies, participants and clinical events prevented the review authors
from making definite conclusions on the effectiveness of these medications. For the same reasons, we could not determine if the
treatment effect differed with age (below 65 years or above 65 years), type of cancer or stage of cancer (metastatic versus non metastatic).
None of the studies tested other anticoagulant treatment including unfractionated heparin, fondaparinux, direct factor Xa inhibitors
or mechanical interventions (intermittent pneumatic compression and graduated elastic stockings).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Low molecular weight heparin (LMWH) compared with placebo or no LMWH for primary thromboprophylaxis in ambulatory cancer patients receiving chemotherapy
Patient or population: ambulatory cancer patients receiving chemotherapy
Settings: outpatient clinics
Intervention: LMWH
Comparison: placebo or no LMWH
Outcomes Illustrative comparative risk (95% CI) Relative effect (95% CI) No of participants (stud-
ies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo or no anticoag-
ulant
LMWH
Symptomatic VTE 44 per 1000 27 per 1000 RR 0.62 [0.41, 0.93] 2464 (6) ⊕⊕⊕
moderate1
Major bleeding 11 per 1000 18 per 1000 RR 1.57 [0.69, 3.60] 2394 (5) ⊕⊕
low3
Symptomatic PE 8 per 1000 5 per 1000 RR 0.63 [0.21, 1.91] 1710 (3) ⊕⊕
low2
1-year mortality 503 per 1000 523 per 1000 RR 1.04 [0.92, 1.16] 1848 (4) ⊕⊕⊕⊕
high
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
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Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded (1 level) because for 3 out of 6 studies it was unclear if adequate concealment of allocation was used
2 Downgraded (2 levels) because out of 6 included studies, only 3 report symptomatic PE; the 95% CI includes both negligible effect and
appreciable benefit or appreciable harm.
3 Downgraded (2 levels) because for 2 out of 5 contributing studies it was unclear if adequate concealment of allocation was used; the
95% CI includes both negligible effect and appreciable benefit or appreciable harm
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Cancer is often complicated by venous thromboembolism (VTE),
which can present as deep vein thrombosis (DVT) or pulmonary
embolism (PE), or both (Khorana 2009). Cancer patients with
VTE have a two-fold or greater increased mortality compared to
cancer patients without thrombosis, which could be explained by
the development of fatal PEs or by a worse prognosis for patients
with those cancers complicated by VTE (Sorensen 2000). VTE in
cancer patients may be hard to recognise due to aspecific symp-
toms which may overlap and be confused with those caused by
the underlying cancer disease process or cancer treatments. VTE
carries significant morbidity due to the need for hospitalisation
and an increased risk of recurrent VTE or bleeding complications,
or both, while on anticoagulation (Hutten 2000; Prandoni 2002).
The occurrence of (unrecognised) VTE may delay the delivery of
cancer treatments such as chemotherapy with a further negative
impact on morbidity and, potentially, mortality. In addition, the
occurrence of venous thromboembolic events brings further emo-
tional strain for patients and their families, which negatively im-
pacts their quality of life. Finally, the costs related to the manage-
ment of VTE may be considerable, resulting from the expenses
related to drugs and hospitalisation.
Description of the condition
The incidence of VTE is higher in patients with cancer compared
to those without cancer. As compared to an incidence of about
0.1% in the general population, the rate of VTE in patients with
cancer has been reported to vary between 0.6% and about 8%
(Khorana 2009). Chemotherapy has been recognised as an inde-
pendent predictor for symptomatic VTE with reported rates of
11% (Otten 2004) up to 75% (Khorana 2009) depending on the
type of chemotherapeutic agent used. The risk of thrombosis in
cancer patients receiving chemotherapy seems to vary based on
the stage of the disease, ranging from 3% to 5% in patients with
early-stage cancer to 30% in those with metastatic or advanced
malignancy (Khorana 2009). Current guidelines recommend sec-
ondary thromboprophylaxis during chemotherapy in cancer pa-
tients with a positive history of VTE (Lyman 2007), whereas the
benefit-risk ratio of primary prophylaxis in such patients is not
well established.
Description of the intervention
Currently available drugs for the prevention of VTE are vitamin
K antagonists, unfractionated heparin, low molecular weight hep-
arins (LMWH) and fondaparinux. In fact, each one of these agents
presents disadvantages for long-term prophylaxis in the ambula-
tory patient with cancer. Heparins and fondaparinux require daily
subcutaneous injections, which represent a considerable burden
for the patient. Vitamin K antagonists require frequent monitor-
ing for dose adjustments and can be difficult to administer because
of nausea and vomiting, poor nutrition and interaction with other
medications. New oral anticoagulants such as direct thrombin and
factor Xa inhibitors offer the potential advantages of oral route
administration, absence of laboratory monitoring requirements,
and fewer pharmacological interactions. In general, the use of an-
ticoagulants in cancer patients is more challenging and is aggra-
vated by a higher rate of recurrent thrombotic events and bleeding
complications relative to patients without cancer (Hutten 2000;
Prandoni 2002). In the study of Prandoni and colleagues the 12-
month cumulative incidence of recurrent VTE and major bleed-
ing were 20.7% and 12.4%, respectively, in patients with cancer
compared to 6.8% and 4.9% in patients without cancer (Prandoni
2002). Interestingly, recurrent VTE and bleeding events were re-
lated to cancer severity and apparently were not explained by sub-
or over-anticoagulation. Possible mechanisms underlying these as-
sociations include the procoagulant state induced by cancer and
treatments for cancer (for example chemotherapy) as well as the
decline in the patient’s general condition leading to immobiliza-
tion. Bleeding at the site of the cancer and the relative decrease
in the number of platelets in the blood (thrombocytopenia) sec-
ondary to chemotherapy may at least partly explain the increase
in bleeding events.
Currently available mechanical interventions for the prevention
of VTE include intermittent pneumatic compression (IPC) and
graduated elastic stockings (GES). These non-pharmacological in-
terventions may be a valid option in cancer patients who are at
risk of bleeding.
Why it is important to do this review
The overall burden of VTE in patients with cancer is steadily
increasing as a result of an aging population, greater awareness,
frequent staging assessments using sensitive imaging techniques,
prothrombotic anticancer treatments as well as the growing cancer
population that is due to the aforementioned aging. Provision of
widespread primary thromboprophylaxis for ambulatory cancer
patients who receive chemotherapy may help prevent this treat-
able complication. However, the efficacy of thromboprophylaxis
needs to be balanced against the risks, such as (major) bleeding
events. We are not aware of any systematic review summarising
the evidence on the benefits and risks of primary pharmacological
prophylaxis in this setting.
O B J E C T I V E S
Our main objective was to compare the efficacy and safety of pri-
mary thromboprophylaxis with placebo or no thromboprophy-
laxis in ambulatory patients with cancer receiving chemotherapy.
The secondary objective was to compare the efficacy and safety of
different types of primary thromboprophylaxis by stratifying the
main results per type of drug and mechanical intervention, and by
aggregating results from head-to-head comparisons.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised and quasi-randomised trials were eligible.
Types of participants
Ambulatory outpatients of any age (including paediatric patients)
with either a solid or haematological cancer, at any stage, and
receiving chemotherapy were eligible. Studies that included pa-
tients with a positive history of VTE at enrolment were excluded if
data could not be extracted separately for those without previous
VTE. Studies evaluating prophylaxis for catheter-related throm-
bosis were excluded since this is already the subject of another
Cochrane review (Akl 2011).
Types of interventions
Interventions included any oral or parenteral anticoagulant (for
example unfractionated heparin, low molecular weight heparin,
vitamin K antagonists, direct thrombin or factor Xa inhibitors)
or mechanical intervention (intermittent pneumatic compression
or graduated elastic stockings), or both, used to prevent VTE in
ambulatory patients with cancer that were receiving chemother-
apy. Comparison interventions included either an inactive control
intervention (placebo, no treatment, standard care) or an active
control intervention (a different scheme or regimen of the same in-
tervention, a different pharmacological type of prophylaxis, a dif-
ferent type of non-pharmacological prophylaxis). Any frequency
or duration of administration, dosage or intensity and timing of
delivery of pharmacological prophylaxis were considered.
Types of outcome measures
Primary outcomes
The main effectiveness outcome was symptomatic VTE objec-
tively verified by means of Doppler (compression) ultrasonogra-
phy or venography for DVT and spiral computed tomography,
ventilation/perfusion lung scan, or pulmonary angiography for
PE. The main safety outcome was major bleeding, typically de-
fined as including: overt bleeding associated with a fall in hae-
moglobin of 2 g/dL or more or leading to a transfusion of two
or more units of packed red blood cells or whole blood; bleeding
that occurred at a critical site (intracranial, intraspinal, intraocu-
lar, pericardial, intra-articular, intramuscular with compartment
syndrome, retroperitoneal); or bleeding contributing to death.
Secondary outcomes
Secondary outcomes included symptomatic PE; symptomatic
DVT; asymptomatic VTE; overall VTE; minor bleeding; one-
year overall mortality; arterial thromboembolic events; superficial
thrombophlebitis; quality of life; number of patients experiencing
any adverse event, and patients experiencing any serious adverse
event. Minor bleeding was defined as a bleeding event not match-
ing the criteria for major bleeding. Serious adverse events were de-
fined as events resulting in inpatient hospitalisation, prolongation
of hospitalisation, persistent or significant disability, congenital
abnormality or birth defect of offspring, life-threatening events
or death. For trials using low molecular weight heparin as the in-
tervention or control, heparin-induced thrombocytopenia (HIT)
and the incidence of osteoporosis, as defined by the authors, were
recorded. We considered all outcomes as binary outcomes except
for quality of life, which was considered as a continuous outcome.
Search methods for identification of studies
Electronic searches
The Cochrane Peripheral Vascular Diseases Group searched
their Specialised Register (last searched 3 May 2011) and the
Cochrane Central Register of Controlled Trials (CENTRAL)
(2011, Issue 2), which is part of The Cochrane Library at
www.thecochranelibrary.com. See Appendix 1 for details of the
search strategy used to search CENTRAL. The Specialised Reg-
ister is maintained by the Trials Search Co-ordinator and is con-
structed from weekly electronic searches of MEDLINE, EM-
BASE, CINAHL and AMED, and through handsearching rele-
vant journals. The full list of the databases, journals and confer-
ence proceedings which have been searched, as well as the search
strategies used, are described in the Specialised Register section of
the Cochrane Peripheral Vascular Diseases Group module in The
Cochrane Library ( www.thecochranelibrary.com).
The authors searched the following clinical trial registries (up to
April 2011) to identify ongoing trials:
• www.clinicaltrials.gov;
• www.controlled-trials.com;
• www.actr.org.au.
Searching other resources
We searched reference lists of identified studies and contacted con-
tent experts and trialists for relevant references. Conference pro-
ceedings of the American Society of Clinical Oncology and the In-
ternational Society of Thrombosis and Haemostasis were screened
up to April 2011 by one review author and any study included if
adequate information could be obtained either from the abstract
or from personal communication.
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Data collection and analysis
Selection of studies
Two review authors independently reviewed titles and abstracts
from the database searches to determine whether the inclusion
criteria were satisfied. Any disagreement was resolved through dis-
cussion between the review authors. The review authors were not
blinded to the journal, institution or results of the study. No lan-
guage restrictions were applied. Studies with insufficient informa-
tion were reassessed if additional information became available
from the authors. Reasons for excluding studies were documented.
In the event of multiple reports relating to the same trial, we con-
sidered them all.
Data extraction and management
Two review authors independently extracted the data from the in-
cluded studies on standardised forms and any disagreements were
resolved by consensus. Collected information included method-
ological quality, characteristics of patients participating in the stud-
ies, characteristics of the intervention and control groups, and
outcome characteristics of every group of participants. Whenever
possible, we extracted results from an intention-to-treat analysis.
If effect sizes could not be calculated, we contacted the authors for
additional data.
Assessment of risk of bias in included studies
Two review authors independently assessed randomisation, blind-
ing and adequacy of analyses (Juni 2001; Rutjes 2009). Disagree-
ments were resolved by consensus.
Two components of randomisation were assessed: generation of
allocation sequence and concealment of allocation. Generation of
allocation sequence was considered adequate if it resulted in an
unpredictable allocation schedule. Mechanisms considered to be
adequate included random-number tables, computer-generated
random numbers, minimisation, coin tossing, shuffling cards and
drawing lots. Trials using an unpredictable allocation sequence
were considered randomised. Trials using potentially predictable
allocationmechanisms, such as alternationor allocationof patients
according to date of birth, date of presentation or case record
number, were considered quasi-randomised.
Concealment of allocation was considered adequate if patients
and investigators responsible for patient selection were unable
to predict before allocation which treatment was next. Methods
considered adequate included central randomisation; pharmacy-
controlled randomisation using identical prenumbered contain-
ers; and sequentially numbered, sealed, opaque envelopes. Blind-
ing of patients and therapists was considered adequate if experi-
mental and control preparations were explicitly described as indis-
tinguishable or if a double-dummy technique was used. Assessors
were considered blinded if this was explicitly mentioned by the
investigators.
Analyses were considered adequate if all randomised patients were
included in the analyses according to the intention-to-treat prin-
ciple. The item ’free of selective reporting’ was classified as at low
risk of bias if we had both the protocol and the full report of a
given study, where the full report presented results for all outcomes
listed in the protocol. We classified a study at high risk of bias if a
report did not present data on all outcomes reported in either the
protocol or themethods section. The risk of bias item ’free of other
bias’ was not considered in this review. We assessed the reporting
of primary outcomes and sample size calculations. Finally, we used
GRADE to describe the quality of the overall body of evidence
(Guyatt 2008; Higgins 2008), which was defined as the extent of
confidence in the estimates of treatment benefits and harms.
Measures of treatment effect
Results are shown as summary risk ratios (RRs) for dichotomous
variables; a 95% confidence interval (CI) was determined for each
estimate. In the case of statistically significant overall estimates, we
also calculated clinical effect summary statistics such as the num-
ber needed to treat to benefit one patient (NNT) or the number
needed to treat to harm one patient (NNH) to express the final
results of the review.
Assessment of heterogeneity
Heterogeneity of the treatment effect between trials was measured
using the I2 statistic (Higgins 2003), which describes the percent-
age of total variation across trials that is attributable to heterogene-
ity rather than to chance. I2 statistic values of 25%, 50% and 75%
may be interpreted as low, moderate and high between-trial het-
erogeneity, respectively, although the interpretation of I2 depends
on the size and number of trials included (Rücker 2008).
Assessment of reporting biases
We evaluated publication bias and other biases related to small
study size using funnel plots, plotting effect sizes on the vertical
axis against their standard errors on the horizontal axis.We assessed
asymmetry by the asymmetry coefficient, the difference in effect
size per unit increase in standard error (Sterne 2001), which is
mainly a surrogate for sample size. Symmetry would be expected
in the absence of any bias related to small study size. Any anomaly
was further explored in stratified analyses in which we investigated
the effects of differences in types of LMWHand suboptimal design
choices on the magnitude of the effects.
Data synthesis
In the main analyses, data were analysed and presented by strati-
fying for the type of thromboprophylaxis used.
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We planned to explore the between trial heterogeneity by strat-
ifying the main outcomes for the following trial characteristics:
age (below 65 years versus above 65 years); type of cancer, stage
of cancer (metastatic versus non-metastatic); type of major bleed-
ing (according to definition versus unclear or different definition);
concealment of allocation (adequate versus inadequate or unclear);
blinding (adequate versus inadequate or unclear); analysis in ac-
cordance with the intention-to-treat principle (yes versus no or
unclear); trial size; and differences in the use of co-interventions
in the trial groups. We planned to use univariate random-effects
meta-regression models (Thompson 1999) to determine whether
treatment effects were affected by these factors and by three con-
tinuous variables at trial level: dosage of intervention, treatment
duration and length of follow up. The data analysis was performed
in RevMan version 5 (Nordic Cochrane Centre, The Cochrane
Collaboration, Copenhagen).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
There were 1328 citations retrieved from the CENTRAL search
and 191 from the Peripheral Vascular Diseases Group Specialised
Register. Following title and abstract screening, 35 were consid-
ered to be potentially eligible. Six additional ongoing studies were
identified from the search of trials registries.
Following full text analysis there were 15 citations for nine studies
that were included in the review and 16 citations to 16 studies
which were excluded. There were 11 citations for ongoing studies.
Included studies
The nine completed randomised controlled trials (RCTs) ran-
domised a total of 3557 participants. None of the included RCTs
used unfractionated heparin (UFH), fondaparinux, direct factor
Xa inhibitors or non-pharmacological prophylaxis as the interven-
tion.
Six studies assessed LMWH as the intervention:
• Agnelli 2009 recruited patients (n = 1150) with metastatic
or locally advanced lung, gastrointestinal, pancreatic, breast,
ovarian or head and neck cancer and randomised them to
nadroparin (3800 IU anti-Xa subcutaneously (sc) once daily (od)
versus placebo. Study treatment started on the same day as
chemotherapy and was given for the duration of the
chemotherapy or up to a maximum of 120 days (± 10 days);
• Altinbas 2004 recruited patients (n = 84) with histologically
confirmed small cell lung carcinoma and randomised them to
standard anticancer treatment with or without dalteparin (5000
IU sc, od). Dalteparin was stopped with disease progression or at
the end of the 18 weeks of chemotherapy;
• Haas 2005 recruited patients (n = 532) with metastatic or
locally advanced lung cancer who received chemotherapy. They
were randomised to six months of certoparin (3000 IU sc, od)
versus placebo. In a second study, the authors randomised 353
patients with advanced breast cancer to the same regimens.
Despite the several emails that we sent to the lead author, we were
unsuccessful in obtaining data on the second trial in advanced
breast cancer patients. We therefore included the data presented
in the abstract and in a related report (see Included studies);
• Kakkar 2004 recruited patients (n = 385) with histologically
confirmed locally advanced or metastatic malignant disease of the
breast, lung, gastrointestinal tract, pancreas, liver, genitourinary
tract, ovary or uterus and randomised them to dalteparin (5000
IU sc, od) versus placebo. Study treatment was given for one year
or until the patient died, whichever occurred sooner;
• Perry 2010 recruited patients (n = 186) with newly
diagnosed, pathologically confirmed World Health Organization
grade 3 or grade 4 glioma and randomised them to six months of
dalteparin (5000 IU sc, od) versus placebo starting within the
first month after surgery. Patients were allowed to continue the
study medication for 12 months;
• Sideras 2006 recruited patients (n = 138) with advanced
breast cancer who did not respond to first-line chemotherapy,
advanced prostate cancer resistant to primary hormonal therapy,
advanced lung cancer, or advanced colorectal cancer. In the first
part of the study patients were randomised to dalteparin (5000
IU sc, od) versus placebo while in the second part patients were
randomised to dalteparin (5000 IU sc, od) plus standard clinical
care versus standard clinical care alone. Dalteparin (or placebo)
was given for 18 weeks or until disease progression.
Levine 1994 recruited patients (n = 311) with metastatic stage
IV breast carcinoma who had been receiving first-line or second-
line chemotherapy for four weeks or less and randomised them to
warfarin versus placebo. Study treatment began either at the start
of chemotherapy or within the next four weeks and continued
until one week after termination of chemotherapy.
Palumbo 2011 recruited patients (n = 667) with previously un-
treated myeloma who received thalidomide-containing regimens
and randomised them to aspirin (100 mg/d), low-dose warfarin
(1.25 mg/d), or lowmolecular weight heparin (enoxaparin 40 mg/
d). The prophylaxis was administered during the three cycles of
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induction therapy in patients ≤ 65 years and during the first six
cycles of induction therapy in patients > 65 years.
Mitchell 2003 recruited paediatric patients (n = 85) newly diag-
nosedwith acute lymphoblastic leukaemia. Theywere treatedwith
L-asparaginase and a functioning central venous line was placed
within two weeks of initiating induction chemotherapy. Patients
were randomised to receive, or not, weekly infusions of antithrom-
bin.
Excluded studies
The reasons for excluding16 studieswere: other design than aRCT
(Meister 2008; Minnema 2004; Paydas 2008); studies on peri-
operative thromboprophylaxis (Bergqvist 1983; Heilmann 1995;
Hills 1972; Macintyre 1974; Maxwell 2000; Sideras 2007; Welti
1981); inclusion of hospitalised cancer patients (Eichinger 2008;
Poniewierski 1987; Poniewierski 1988); no relevant outcomes re-
ported (Rajan 1995); no eligible intervention (Klerk 2005); pro-
phylaxis was for catheter-related thrombosis (Kwaan 2007).
Risk of bias in included studies
The risk of bias in the included studies is shown in Figure 1.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Allocation was adequately concealed in six studies included in the
meta-analysis (Agnelli 2009; Kakkar 2004; Levine 1994; Mitchell
2003; Palumbo 2011; Perry 2010) and was unclear in the remain-
der (Altinbas 2004; Haas 2005; Sideras 2006) because the infor-
mation was not provided.
Blinding
Five studies had a double-blinded design (Agnelli 2009; Haas
2005; Kakkar 2004; Levine 1994; Perry 2010), three were open.
Incomplete outcome data
Two studies performed the analysis according to the intention-
to-treat principle (Altinbas 2004; Perry 2010) while in five stud-
ies the percentages of patients randomised and subsequently ex-
cluded from the analysis ranged from1.3% to 2.8% (Agnelli 2009;
Kakkar 2004; Levine 1994; Palumbo 2011; Sideras 2006). The
study on paediatric patients used a per protocol analysis and ex-
cluded 22% of the patients initially enrolled (Mitchell 2003); it
was considered at high risk of bias. The type of analysis and the
percentage of patients enrolled and subsequently excluded from
the analysis was unclear in the study of Haas 2005.
Selective reporting
All studies were judged to be free of selective reporting except the
study of Perry 2010, which did not report data on the prespecified
outcomes of quality of life and cognition assessment. In the study
of Palumbo 2011, the number of adverse events was not reported
in the final report. For the study of Haas 2005 selective reporting
was unclear due to poor reporting.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table
See: Summary of findings for the main comparison.
Anticoagulants versus control
LMWH versus inactive control
Based on pooled estimates from six RCTs, LMWH when com-
pared with placebo was associated with a significant reduction in
symptomatic VTE (RR 0.62, 95% CI 0.41 to 0.93) which corre-
sponded to a NNT of 60 (Figure 2), in the absence of heterogene-
ity (I2 = 0%). Funnel plot exploration did not show any evidence
of biases associated with small studies (Figure 3). Data suggested a
60% increased risk of major bleeding, albeit this finding was not
statistically significant (RR 1.57, 95% CI 0.69 to 3.60) (Figure
4), with low-degree heterogeneity (I2 = 10%) in the absence of
funnel plot asymmetry (Figure 5). There was no significant effect
on symptomatic PE (RR 0.63, 95% CI 0.21 to 1.91; I2 = 3%)
or DVT (RR 0.60, 95% CI 0.33 to 1.07; I2 = 0%). The risk
of overall VTE was reduced by 45% (RR 0.55, 95% CI 0.34 to
0.88; I2 = 0%) whereas there was no statistically significant benefit
or harm for asymptomatic VTE, minor bleeding, one-year mor-
tality, symptomatic arterial thromboembolism, superficial throm-
bophlebitis or serious adverse events (Data and analyses). None of
the studies considered quality of life, heparin-induced thrombo-
cytopenia or the incidence of osteoporosis as study outcomes.
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Figure 2. Forest plot of comparison: 1 Anticoagulants versus control, outcome: 1.1 Symptomatic VTE for
LMWH vs placebo.
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Figure 3. Funnel plot of comparison: 1 Anticoagulants versus control, outcome: 1.1 Symptomatic VTE for
LMWH vs placebo.
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Figure 4. Forest plot of comparison: 2 Anticoagulants versus control, outcome: 2.1 Major bleeding for
LMWH vs placebo.
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Figure 5. Funnel plot of comparison: 2 Anticoagulants versus control, outcome: 2.1 Major bleeding for
LMWH vs placebo.
The low-degree heterogeneity for major bleeding was investigated
further in stratified analysis. For type of cancer, stage of cancer or
differences in the use of co-interventions there was not enough
contrast between the trials groups for the analysis. All other pre-
specified variables had no significant interaction with the LMWH
effect on bleeding (See Table 1). In general, suboptimal design fea-
tures seemed to be associated with lower effect sizes. For example,
when only studies with both adequate sequence generation and
allocation concealment were considered (Agnelli 2009; Kakkar
2004; Perry 2010) a four-fold increased risk of major bleeding
with LMWH was observed, with a wide confidence interval that
crossed the ’no difference’ value of 1 (RR 4.25, 95% CI 0.94 to
19.24; P = 0.24).
Three studies reported on symptomatic VTE and major bleed-
ing in patients with non-small cell (Haas 2005) or small cell lung
cancer (Altinbas 2004), or both (Agnelli 2009). Pooled analysis
of these trials showed a non-significant 46% reduction in symp-
tomatic VTE (RR 0.54, 95% CI 0.27 to 1.09) and a non-signifi-
cant 73% higher risk of major bleeding with LMWH as compared
to the control treatment (RR 1.73, 95% CI 0.65 to 4.57), with
no evidence of statistical heterogeneity (I2 = 0%).
LMWH versus active control
In the study of Palumbo 2011 LMWHwas associated with a 67%
reduction in symptomatic VTE relative to warfarin (RR 0.33,
95% CI 0.14 to 0.83) while the difference with aspirin was not
statistically significant (RR0.50, 95%CI0.19 to 1.31). Therewere
no differences between LMWH, aspirin and warfarin regarding
the incidence of major bleeding, symptomatic PE or DVT, minor
bleeding and symptomatic arterial thromboembolism.
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VKA versus inactive control
Levine 1994 reported a trend for a reduction in symptomatic VTE
(RR 0.15, 95% CI 0.02 to 1.20) relative to placebo. There was
no significant effect on major bleeding (RR 0.52, 95% CI 0.05
to 5.71), symptomatic PE (RR 1.05, 95% CI 0.07 to 16.58),
symptomatic DVT (RR 0.08, 95% CI 0.00 to 1.42) or minor
bleeding (RR2.44, 95%CI0.64 to 9.27).No symptomatic arterial
thromboembolic events were observed in the VKA or placebo
groups.
VKA versus active control
Palumbo 2011 reported a non-statistically significant difference
between VKA and aspirin (RR 1.50, 95% CI 0.74 to 3.04). We
refer to the previous section for the description of the comparison
of VKA with LMWH.
Antithrombin versus inactive control
Antithrombin was assessed in one study that recruited paediatric
patients (Mitchell 2003). The effects of antithrombin on symp-
tomatic VTE (RR 0.84, 95%CI 0.41 to 1.73) and major bleeding
(RR 0.78, 95%CI 0.03 to 18.57) were not statistically significant.
D I S C U S S I O N
Summary of main results
The use of LMWHas primary thromboprophylaxis in ambulatory
cancer patients receiving chemotherapy is associated with a 40%
reduction in symptomatic VTE. Data suggested a non-statistically
significant 60% higher risk of major bleeding, but confidence in-
tervals were wide and thus the finding inconclusive. The available
data did not show any statistically significant effect of LMWH
on PE or mortality, and no study reported on thrombocytope-
nia or osteoporosis. The lack of a placebo or non-active control
group does not allow firm judgements about the efficacy and sa-
fety of LMWH in myeloma patients. The effect of warfarin on
symptomatic VTE was not statistically significant and antithrom-
bin was evaluated in a relatively small study involving paediatric
patients. None of the included RCTs tested UFH, fondaparinux,
direct factor Xa inhibitors or mechanical interventions.
Quality of the evidence
Our systematic approach to searching, study selection and data ex-
traction followed that of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2003). The methodological quality
of the included studies varied from low to high, see Summary of
findings for the main comparison and Figure 1. An inspection of
the funnel plot and formal analysis of asymmetry did not indicate
asymmetry for primary efficacy and safety outcomes (see Figure 3;
Figure 5).
Potential biases in the review process
Our systematic approach and the consistency of the results (lack of
significant heterogeneity) increase the confidence in the internal
validity of our findings. One limitation of this review is that the
’no difference’ findings may be related to the small number of
RCTs and small number of studied patients and of events, as well
as the absence of a true effect. In this regard, the non-significant
association between LMWH use and major bleeding events could
indeed be the result of the relatively lownumber of events observed
across the studies. Another limitation related to the small number
of RCTs was our inability to conduct subgroup analyses for the
primary efficacy outcomeby exploring the impact on the treatment
effect of age (below 65 years versus above 65 years); type of cancer,
stage of cancer (metastatic versus non-metastatic); concealment
of allocation (adequate versus inadequate or unclear); blinding
(adequate versus inadequate or unclear); analysis in accordance
with the intention-to-treat principle (yes versus no or unclear);
trial size; and differences in the use of co-interventions in the trial
groups. The lack of reporting as well as the heterogeneity of cancers
treated did not allow us to assess the importance of background
chemotherapy on the response to thromboprophylaxis.
Agreements and disagreements with other
studies or reviews
The evidence on the use of thromboprophylaxis in ambulatory
cancer patients receiving chemotherapy was recently summarised
by the American Society of Clinical Oncology (Rana 2009). Rel-
ative to that narrative review, we included five additional stud-
ies (Altinbas 2004; Kakkar 2004; Mitchell 2003; Palumbo 2011;
Sideras 2006). Three of these studies evaluated the effects of
prophylactic doses of LMWH on survival as the primary out-
comewhile reportingVTE events as secondary outcomes (Altinbas
2004; Kakkar 2004; Sideras 2006). Although the focus was not
on VTE and some cases may have been under-diagnosed, the
overall incidence of symptomatic VTE was comparable with the
other studies included in the review. Overall, themain conclusions
of Rana 2009 are substantially in line with our findings and do
not support the widespread use of primary thromboprophylaxis
in ambulatory cancer patients. The pooled estimates provided in
the present meta-analysis underline the need for additional studies
to confirm the benefit of prophylaxis on ’hard’ outcomes such as
symptomatic PE, but also to exclude a significant increase inmajor
bleeding with LMWH.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When deciding whether to use primary antithrombotic prophy-
laxis in ambulatory cancer patients receiving chemotherapy, a clin-
ician needs to determine the patients’ baseline risk of VTE and
weigh themagnitude of benefit, especially on clinically major end-
points, with antithrombotic prophylaxis against the risk of bleed-
ing. LMWH was associated with a 40% lower incidence of symp-
tomatic VTE. Albeit not statistically significant, the rate of symp-
tomatic PE was reduced to a similar extent. LMWH was associ-
ated with a 60% increase in major bleeding when compared with
inactive control but the confidence interval was wide and crossed
the line of no difference. This finding could still be the result of
the relatively small size of the population or low number of events
(type II error). Co-morbidities predisposing to bleeding, which
often represent an exclusion criterion in randomised controlled
studies on anticoagulants, might result into higher major bleeding
complications and limit the use of thromboprophylaxis in ’real
life’. An additional concern may be the use of thromboprophy-
laxis in some types of cancers, such as those in the brain, which
are considered to be at risk for major bleeding. Thus, despite the
encouraging results of this review, routine prophylaxis in ambula-
tory cancer patients cannot be recommended before safety issues
are adequately addressed. Specific patients subgroups that might
benefit from prophylaxis cannot be specified.
Implications for research
Future studies are needed to clearly establish the risk to bene-
fit ratio of anticoagulants in ambulatory cancer patients receiv-
ing chemotherapy and to identify subgroups which may benefit
most from thromboprophylaxis. Moreover, evidence-based bleed-
ing risk assessment scores may help in selecting subgroups at lower
risk of bleeding complications. Research is needed to evaluate the
effects of newer anticoagulants such as direct Xa inhibitors and
direct thrombin inhibitors, which have shown promise compared
to heparin or vitamin K antagonists in other settings.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agnelli 2009
Methods Prospective, multicentre RCT; modified intention-to-treat analysis
Participants Ambulatory patients older than 18 years of age who were receiving chemotherapy
for metastatic or locally advanced lung, gastrointestinal, pancreatic, breast, ovarian,
or head and neck cancer. Age: 62.1 years in the nadroparin group; 63.7 years in the
placebo
Interventions Nadroparin (3800 IU anti-Xa sc, od)
Control: placebo
Study treatment started on the same day as chemotherapy (the first cycle or a new course)
, and given for the duration of chemotherapy or up to a maximum of 120 days (±10
days)
Outcomes Primary outcomes:
1) composite of symptomatic venous or arterial thromboembolic events occurringduring
the study treatment plus 10 days
2) major bleeding that occurred between randomisation and 48 h after the last injection
of the study drug
Secondary efficacy outcomes: asymptomatic thromboembolic events incidentally diag-
nosed, survival at the end of study treatment and at 12 months, superficial throm-
bophlebitis of the lower limbs, response to chemotherapy, central venous catheter-related
complications of possible thrombotic origin
Secondary safety outcome: minor bleeding
Notes Antiplatelet agents, oral anticoagulants, fibrinolytic agents, unfractionated heparin or
lowmolecular weight heparin other than nadroparin not allowed during the study period
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Web-based system
Allocation concealment (selection bias) Low risk Web-based system
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Percentage of patients enrolled and subse-
quently excluded from the analysis: 1.4%
(16/1166)
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Agnelli 2009 (Continued)
Selective reporting (reporting bias) Low risk The report includes all expected outcomes
Altinbas 2004
Methods RCT; intention-to-treat analysis
Participants Patients between ages 18 and 75 years with histologically confirmed small cell lung
carcinoma with an Eastern Cooperative Oncology Group performance status of less
than 3 and normal hematological, renal and hepatic function tests. Median age: 58 years
(range 34-75)
Interventions Dalteparin (5000 IU sc, od)
Control: no dalteparin
Dalteparin stopped with disease progression or at the end of the 18 weeks of chemother-
apy
Outcomes Primary outcome: overall survival
Secondary outcomes: progression-free survival, side-effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
High risk Open study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Percentage of patients enrolled and subsequently ex-
cluded from the analysis: 0%
Selective reporting (reporting bias) Low risk The report includes all expected outcomes
Haas 2005
Methods RCT
Participants Patients with advanced breast cancer (n = 353) or non-small cell lung carcinoma (n =
547) who received chemotherapy
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Haas 2005 (Continued)
Interventions Certoparin (3000 IU sc, od) for 6 months
Control: placebo
Outcomes Primary outcomes: symptomatic VTE and asymptomatic DVT
Secondary outcomes: major bleeding
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided in the abstract
Allocation concealment (selection bias) Unclear risk No information provided in the abstract
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided in the abstract
Selective reporting (reporting bias) Unclear risk No information provided in the abstract
Kakkar 2004
Methods Prospective, multicentre RCT; intention-to-treat analysis
Participants Patients of 18 and 80 years with histologically confirmed advanced stage III or IV
(locally advanced or metastatic) malignant disease of the breast, lung, gastrointestinal
tract, pancreas, liver, genitourinary tract, ovary, or uterus. Age: 62 years in the dalteparin
group and 60.9 years in the placebo
Interventions Dalteparin (5.000 IU sc, od)
Control: placebo (0.9% normal saline).
Study treatment given for 1 year or until the patient died, whichever occurred sooner
Outcomes Primary outcomes: mortality after 1 year of therapy
Secondary outcomes:symptomatic, objectively confirmed VTE disease and bleeding
complications
Notes
Risk of bias
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Kakkar 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Web-based system
Allocation concealment (selection bias) Low risk Web-based system
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Percentage of patients enrolled and subse-
quently excluded from the analysis: 2.8%
(11/385)
Selective reporting (reporting bias) Low risk The report includes all expected outcomes
Levine 1994
Methods Prospective, multicentre RCT; intention-to-treat analysis
Participants Patients with metastatic stage IV breast carcinoma who had been receiving first-line or
second-line chemotherapy for 4 weeks or less. Mean age: 57 years in the warfarin group
and 56 years in the placebo
Interventions Warfarin (1 mg daily for 6 weeks and then adjusted to maintain the INR between 1.3
to 1.9)
Control: placebo
Study treatment began either at the start of chemotherapy or within the next 4 weeks
and continued until 1 week after termination of chemotherapy
Outcomes Primary outcomes:
1) VTE and arterial thrombosis
2) major and minor bleeding
Secondary outcomes: survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Web-based system
Allocation concealment (selection bias) Low risk Web-based system
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Levine 1994 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Percentage of patients enrolled and subse-
quently excluded from the analysis: 1.3%
(4/315)
Selective reporting (reporting bias) Low risk The report includes all expected outcomes
Mitchell 2003
Methods Prospective RCT; per protocol analysis
Participants Paediatric patients newly diagnosed with acute lymphoblastic leukaemia treated with L-
asparaginase and a functioning central venous line placed within 2 weeks of initiating
induction chemotherapy
Interventions Thrombate III (infusions once weekly for 4 weeks to increase plasma concentrations of
antithrombin to approximately 3.0 units/mL but no more than 4.0 units/mL)
Control: standard care
Outcomes Primary outcomes:
1) clinically symptomatic or asymptomatic thrombotic event in any location
2) major and minor bleeding
Secondary outcomes: surrogate outcome for thrombotic events by measuring markers
of thrombin generation
Notes Patients did receive small amounts of UFH for prophylaxis of central venous line-block-
age either by continuous infusion (1-3 units/mL) or intermittent flushes (50-100 units/
mL up to 4 times per day) according to local standard of care
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Web-based system
Allocation concealment (selection bias) Low risk Web-based system
Blinding (performance bias and detection
bias)
All outcomes
High risk Open study
Incomplete outcome data (attrition bias)
All outcomes
High risk Percentage of patients enrolled and subse-
quently excluded from the analysis: 22% (24/
109)
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Mitchell 2003 (Continued)
Selective reporting (reporting bias) Low risk The report includes all expected outcomes
Palumbo 2011
Methods Randomised, open-label, multicentre study, intention-to-treat analysis
Participants Patients with previously untreated myeloma who received thalidomide-containing reg-
imens and had no clinical indication or contraindication for a specific antiplatelet or
anticoagulant therapy. Median age: aspirin 61 years (55 - 66), warfarin 60 years (54 -
66), heparin 62 years (55 - 66)
Interventions Aspirin (100 mg/d), low-dose warfarin (1.25 mg/d), or LMWH (enoxaparin 40 mg/
d). The prophylaxis was administered during the three cycles of induction therapy in
patients ≤ 65 years and during the first six cycles of induction therapy in patients > 65
years
Outcomes Primary endpoint:
a composite measure of a first episode of objectively confirmed symptomatic DVT,
PE, arterial thrombosis, acute myocardial infarction or stroke, or sudden, otherwise
unexplained death during the first 6 months from random assignment
Secondary endpoints:
-each component of the composite primary end point
-long-term cumulative incidence of the primary end point
-major and minor bleeding events
-any toxicity that required interruption of study prophylaxis
Notes Karnofsky performance status <70%: aspirin 25%, warfarin 29%, heparin 30%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignment sequence was gener-
ated by a centralised computer
Allocation concealment (selection bias) Low risk Patients randomly allocated to treatments
using an automated assignment procedure
concealed to the investigators
Blinding (performance bias and detection
bias)
All outcomes
High risk Open study
Incomplete outcome data (attrition bias)
All outcomes
High risk Percentage of patients enrolled and subse-
quently excluded from the analysis: 1.36%
(9/659)
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Palumbo 2011 (Continued)
Selective reporting (reporting bias) Unclear risk The number of adverse events in the treat-
ment groups not reported in the final re-
port
Perry 2010
Methods Prospective, multicentre RCT; intention-to-treat analysis
Participants Patients over 18 years of age with newly diagnosed, pathologically confirmed WHO
Grade 3 or Grade 4 glioma
Interventions Dalteparin (5000 IU sc, od)
Control: placebo
Study treatment given for 6 months starting within the first month after surgery. Patients
allowed to continue study medication for 12 months
Outcomes Primary outcomes: objectively documented symptomatic DVT or PE occurring during
the six months post-randomisation
Secondary outcomes: major and all bleeding, quality of life, cognition assessments, and
death
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Web-based system
Allocation concealment (selection bias) Low risk Web-based system
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Percentage of patients enrolled and subse-
quently excluded from the analysis: 0% (0/
186)
Selective reporting (reporting bias) High risk The outcomes quality of life and cognition
assessment not reported in the final report
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Sideras 2006
Methods RCT
Participants Patients with advanced breast cancer who failed first-line chemotherapy, advanced
prostate cancer who failed primary hormonal therapy, advanced lung cancer, or advanced
colorectal cancer
Interventions First part of the study, double blinded (52 patients):
Dalteparin (5000 IU sc, od) plus standard clinical care
Control: placebo (saline injections) plus standard clinical care
Second part of the study, open (86 patients)
Dalteparin (5000 IU sc, od) plus standard clinical care
Control: standard clinical care alone.
Duration: 18 weeks or until disease progression
Outcomes Primary outcome: overall survival
Secondary outcomes: toxic effects, incidence of thromboembolic events, changes in
quality of life
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
High risk Double blinding in the first part of the trial, open in the second
part
Incomplete outcome data (attrition bias)
All outcomes
High risk Percentage of patients enrolled and subsequently excluded from
the analysis: 2.1% (3/141)
Selective reporting (reporting bias) Low risk The report includes all expected outcomes
od: once daily
sc: subcutaneous
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bergqvist 1983 Perioperative thromboprophylaxis
Eichinger 2008 Inadequate population: hospitalised cancer patients
Heilmann 1995 Perioperative thromboprophylaxis
Hills 1972 Perioperative thromboprophylaxis
Klerk 2005 Inadequate intervention, not primary thromboprophylaxis
Kwaan 2007 Prophylaxis for catheter-related thrombosis
Macintyre 1974 Perioperative thromboprophylaxis
Maxwell 2000 Perioperative thromboprophylaxis
Meister 2008 Not a RCT
Minnema 2004 Not a RCT
Paydas 2008 Not a RCT
Poniewierski 1987 Inadequate population: hospitalised cancer patients
Poniewierski 1988 Inadequate population: hospitalised cancer patients
Rajan 1995 Inadequate outcomes
Sideras 2007 Perioperative thromboprophylaxis
Welti 1981 Perioperative thromboprophylaxis
Characteristics of studies awaiting assessment [ordered by study ID]
Salat 1990
Methods Prospective RCT
Participants Patients (n = 80) with malignant diseases
Interventions Unfractionated heparin (2 x 7500 IU/mL)
Control: dalteparin (5000 IU sc, od)
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Salat 1990 (Continued)
Outcomes Thrombosis and haemorrhagic complications
Notes
od: once daily
sc: subcutaneous
Characteristics of ongoing studies [ordered by study ID]
Anon 2006
Trial name or title A randomised, double-blind, placebo-controlled study of apixaban for the prevention of thromboembolic
events in patients undergoing treatment for advanced cancer: a phase II pilot study
Methods Unclear methods of randomisation, allocation concealment and analysis; double blinded
Participants Patients with advanced or metastatic cancer receiving chemotherapy ≥ 90 days entering the study within six
weeks from the start of chemotherapy
Interventions Apixaban (5 mg oral, qd)
Control: placebo
Study treatment given for 12 weeks
Outcomes Primary outcome: fatal or non-fatal major bleeding or a clinically relevant non-major bleeding event during
the treatment period
Secondary outcome: symptoms compatible with VTE during the treatment and 30 day follow-up periods
Starting date June 2006
Contact information Bristol-Myers Squibb
Notes
Francis 2009
Trial name or title A prospective randomised multicentre study of dalteparin prophylaxis in high-risk ambulatory cancer patients
Methods Unclear methods of randomisation, allocation concealment and analysis; open label
Participants Patients with a histologic diagnosis ofmalignancy, planned initiation of a new systemic chemotherapy regimen,
and a risk score for VTE ≥ 3
Interventions Dalteparin (5000 IU sc, od)
Control: no dalteparin
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Francis 2009 (Continued)
Outcomes Primary outcome: safety and efficacy of prophylaxis with dalteparin compared to no treatment in reducing
VTE
Secondary outcome: value of tissue factor as a predictive marker for VTE
Starting date July 2009
Contact information Francis C
Notes
Griffiths 2009
Trial name or title FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin added to standard
therapy in patients with lung
cancer
Methods Central randomisation using the method of minimisation and stratifying patients for a number of factors;
open-label, planned intention-to-treat analysis
Participants Patients with histopathological or cytological diagnosis of primary bronchial carcinoma (small cell or non-
small cell) within the last 6 weeks, age 18 or over, ECOG Performance status 0 to 3
Interventions Dalteparin (5000 IU sc, od) plus standard anticancer treatment; dalteparin is given for 24 weeks and started
as soon as possible and before first definitive anticancer treatment
Control: standard anticancer treatment
Outcomes Primary outcome: overall survival
Secondary out comes: venous thrombotic event free survival, serious adverse events, metastasis-free survival,
toxicity, quality of life, breathlessness, anxiety and depression, cost effectiveness, cost utility
Starting date
Contact information Griffiths GO: griffithsg@cardiff.ac.uk
Notes
Levin 2008
Trial name or title A randomised phase II trial of aspirin for primary prophylaxis of VTE in glioblastoma
Methods Unclear methods of randomisation, allocation concealment and analysis; double blinded
Participants Patientswith histologically proven supratentorialmalignantWHOgrade IV gliomas documented onmagnetic
resonance imaging or computed tomography, Karnofsky performance status ≥ 60 at study entry, no more
than 16 weeks from the diagnosis of glioblastoma
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Levin 2008 (Continued)
Interventions Aspirin (325 mg oral, od)
Control: placebo
Outcomes Primary outcome: VTE
Secondary outcomes: clinical and laboratory factors which are associated with increased risk of VTE
Starting date November 2008
Contact information Levin VA
Notes
Liebman 2009
Trial name or title Apixaban in patients with metastatic cancer: a randomised phase II feasibility study
Methods Unclear methods of randomisation, allocation concealment, analysis. Double blinding
Participants Patients with metastatic cancer on first or second-line chemotherapy
Interventions Apixaban 5, 10, or 20 mg/day
Comparator: placebo
Duration of treatment: 12 weeks
Outcomes Major bleeding, clinically relevant non-major bleeding, VTE, grade > 3 adverse events
Starting date Not available from the abstract
Contact information Liebman H
Notes
Maraveyas 2003
Trial name or title A phase II randomised study of chemo-anticoagulation (Gemcitabine-Dalteparin) vs chemotherapy alone
(Gemcitabine) for locally advanced and metastatic pancreatic adenocarcinoma
Methods Multicentre randomised controlled trial
Participants Participants with:
1. Histologically or cytologically confirmed metastatic or locally advanced adenocarcinoma of the pancreas
(patients with clinical ’high probability’ of pancreatic cancer and biopsy suggestive but not diagnostic of
pancreatic cancer may be eligible based on review by the principal investigator)
2. Measurable or evaluable disease
3. Karnofsky performance status (PS) 60-100% OR WHO PS 0-2
4. Life expectancy > 12 weeks
5. Absolute neutrophil count > 2,000/mm³
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Maraveyas 2003 (Continued)
6. WBC > 3,000/mm³
7. Platelet count > 100,000/mm³
8. Creatinine clearance > 50 mL/min
9. INR ≤ 1.5 times upper limit of normal (ULN)
10. Bilirubin < 1.5 times ULN (stent allowed)
11. Adequate contraceptive measures in place
Interventions Patients are stratified according to disease progression (locally advanced vs metastatic) and Karnofsky perfor-
mance status (≥80% vs < 80%), then randomised to 1 of 2 treatment arms:
Arm I: Patients receive gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 1-7 and 9-11.
Arm II: Patients receive LMWH dalteparin sc od in weeks 1-12. Patients also receive gemcitabine hydrochlo-
ride as in Arm I
Outcomes Primary outcome: Incidence of VTE reduction
Secondary outcomes:
1. Early survival benefits
2. Toxicity
3. Overall survival
4. Time to disease progression
5. Effect of drug combination on serological markers of thromboangiogenesis
Starting date 06/01/2003
Contact information Maraveyas A - mdsam@doctors.org.uk
Notes Data of a substudy onmolecularmarkers only was published inMay 2010 (BloodCoagulation and Fibrinolysis
2010;21(5):452-8)
Oettle 2004
Trial name or title A prospective, randomised trial of simultaneous pancreatic cancer treatment with enoxaparin and chemo-
therapy
Methods Unclear methods of randomisation, allocation concealment, analysis, and blinding
Participants Patients of 18 years or older with histologically or cytologically proven advanced pancreatic cancer stage Iva, b,
no previous tumour specific therapy of the main tumour or distant metastases, Karnofsky performance status
greater than 50%, measurable disease visible per computed tomography or magnetic resonance tomography
not older than 14 days, no previous DVT of the legs within last two years, leucocytes greater than 3.5 x 10ˆ9/
L, platelets greater than 100 x 10ˆ9/L
Interventions Patients with Karnofsky performance status greater than 80% and normal kidney function:
Enoxaparin (1 mg/kg sc, od) plus gemcitabine, cisplatin, 5-fluorouracil and folinic acid
Control: gemcitabine, cisplatin, 5-fluorouracil and folinic acid
Patients with Karnofsky performance status less than 80% and increased creatinine plasma levels (greater than
1.3 mg/dl):
Enoxaparin (1 mg/kg sc, od) plus gemcitabine
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Oettle 2004 (Continued)
Control: gemcitabine
Outcomes Primary outcome: thromboembolic events
Secondary outcomes
1. Thromboembolic rate at time points 6, 9 and 12 months
2. Time to progression
3. Overall survival, progression-free survival
4. Rate of remission, duration of remission
5. Toxicity: National Cancer Institute Common Toxicity Criteria grade differentiation
6. Quality of life
Starting date April 2004
Contact information Oettle H
Notes
Riess 2008
Trial name or title Rationale and design of PROSPECT-CONKO 004: a prospective, randomised trial of simultaneous pancre-
atic cancer treatment with enoxaparin and chemotherapy
Methods Prospective, open-label, randomised, phase IIb study
Participants Patients of 18 years or older with histologically or cytologically confirmed locally advanced or metastasised
pancreatic cancer who are treated with a palliative chemotherapy using either gemcitabine alone or in combi-
nation with cisplatin, 5-fluorouracil and folinic acid, who have not received previous radio- or chemotherapy
of the primary tumour or the reference lesions; and who have Karnofsky performance status ≥ 60%; mea-
surable tumour lesion confirmed by computed tomography or magnetic resonance tomography within the
last 14 days; no DVT within the last two years, leucocytes greater than 3.5 x 10ˆ9/L, thrombocytes ≥ 100 x
10ˆ9/L
Interventions Enoxaparin (1 mg/kg sc, qd for the first three months followed by 40 mg qd for an additional three months)
plus standard anticancer treatment
A reduction of enoxaparin to 0.5 mg/kg is recommended if thrombocytes are between 50,000 and 75,000/µl
until an increase in thrombocytes > 75,000/µl. Enoxaparin is to be interrupted in thrombocytopenia below
50,000/µl
Control: standard anticancer treatment
Outcomes Primary outcome: clinically relevant VTE within the first three months
Secondary outcomes: symptomatic and asymptomatic VTE after 6, 9 and 12 months; remission at 3, 6, 9 and
12 months, overall survival, rates of remission at 3, 6, 9 and 12 months, toxicity of the therapeutic regimen,
time to tumour regression and quality of life during chemotherapy with or without enoxaparin and the rate
of major bleeding
Starting date
Contact information Hanno Riess - hanno.riess@charite.de
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Riess 2008 (Continued)
Notes
Turpie 2008
Trial name or title A multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety
of AVE5026 in the prevention of VTE in cancer patients at high risk for VTE and who are undergoing
chemotherapy
Methods Randomised, double-blind, placebo-controlled
Participants Patients with metastatic or locally advanced solid tumours of lung, pancreas, stomach, colon/rectum, bladder
or ovary initiating a (new) course of chemotherapy with a minimum intent of three months therapy
Interventions AVE5026 (sc, od)
Control: placebo
Outcomes Primary outcome: time-to-first occurrence of symptomatic DVT of lower or upper limbs, non-fatal PE, and
VTE-related deaths from randomisation up to three calendar days after last study drug injection
Secondary outcomes: individual components of the primary outcome measure from randomisation up to
three calendar days after last study drug injection; bleedings, transfusions, laboratory data, adverse events,
deaths during study period
Starting date June 2008
Contact information Turpie A
Notes
Vadhan-Raj 2010
Trial name or title Randomised clinical trial of dalteparin for primary VTE prophylaxis in pancreatic cancer patients undergoing
chemotherapy treatment
Methods Unclear methods of randomisation, allocation concealment and analysis; open label
Participants Patients 18 years or older with a diagnosis of advanced stage (unresectable or metastatic) adenocarinoma of
the pancreas planning to initiate systemic chemotherapy within two weeks, ECOG performance status 0 - 2,
adequate renal function (creatinine clearance of > 50 mL/min)
Interventions Dalteparin (5000 IU sc, od) for 16 weeks
Control: no dalteparin
Outcomes Primary outcome: venous thromboembolic events during 16 weeks of treatment
Starting date April 2010
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Vadhan-Raj 2010 (Continued)
Contact information Vadhan-Raj S
Notes
Zwicker 2009
Trial name or title A randomised controlled trial of enoxaparin thromboprophylaxis in cancer patients with elevated tissue factor
bearing microparticles
Methods Unclear methods of randomisation, allocation concealment and analysis; open label
Participants Patients 18 year old or older with histologically confirmed adenocarcinoma of the pancreas (locally advanced
ormetastatic), colon (stage IV), or lung (unresectable stage III or IV ) and for which standard curative therapies
do not exist., who receive first or second line therapy (within 4 weeks of initiating therapy), life expectancy
of greater than six months, ECOG performance status 0, 1, or 2 (Karnofsky 60% or greater)
Interventions Enoxaparin (sc od) for six months
Control: B and C (high and low tissue factor bearing microparticles): no enoxaparin
Outcomes Primary outcome: VTE events during three years
Secondary outcomes: major bleeding, overall survival, symptomatic or proximal VTE events at six months,
cumulative incidence of total VTE events in cancer patients with low tissue factor bearing microparticles
compared with those with high tissue factor bearing microparticles not treated with enoxaparin, influence
of chemotherapy or enoxaparin on tissue factor bearing microparticles levels, association between absolute
tissue factor bearing microparticles levels and thrombotic risk
Starting date May 2009
Contact information Zwicker J
Notes
od: once daily
qd: four times daily
sc: subcutaneous
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D A T A A N D A N A L Y S E S
Comparison 1. Anticoagulants versus control: symptomatic VTE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic VTE: LMWH vs
placebo
6 2464 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.41, 0.93]
1.1 Dalteparine 4 782 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.42, 1.32]
1.2 Certoparine 1 532 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.23, 1.22]
1.3 Nadroparin 1 1150 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.22, 1.09]
2 Symptomatic VTE: LMWH vs
aspirin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Symptomatic VTE: LMWH vs
warfarin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Symptomatic VTE: vitamin K
antagonists vs placebo
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Symptomatic VTE: warfarin vs
aspirin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Symptomatic VTE:
antithrombin vs placebo
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 2. Anticoagulants versus control: major bleeding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Major bleeding: LMWH vs
placebo
5 2394 Risk Ratio (M-H, Random, 95% CI) 1.57 [0.69, 3.60]
1.1 Dalteparine 3 698 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.26, 7.29]
1.2 Certoparine 1 546 Risk Ratio (M-H, Random, 95% CI) 1.67 [0.61, 4.52]
1.3 Nadroparin 1 1150 Risk Ratio (M-H, Random, 95% CI) 5.46 [0.30, 98.43]
2 Major bleeding: LMWH vs
aspirin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Major bleeding: LMWH vs
warfarin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Major bleeding: vitamin K
antagonists vs placebo
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Major bleeding: warfarin vs
aspirin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Major bleeding: antithrombin vs
placebo
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Comparison 3. Anticoagulants versus control: symptomatic PE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic PE: LMWH vs
placebo
3 1710 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.21, 1.91]
1.1 Dalteparin 2 560 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.11, 10.25]
1.2 Nadroparin 1 1150 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.10, 2.44]
2 Symptomatic PE: LMWH vs
aspirin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Symptomatic PE: LMWH vs
warfarin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Symptomatic PE: vitamin K
antagonists vs placebo
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Symptomatic PE: warfarin vs
aspirin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 4. Anticoagulants versus control: symptomatic DVT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic DVT: LMWH vs
placebo
4 1794 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.33, 1.07]
1.1 Dalteparin 3 644 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.32, 1.39]
1.2 Nadroparin 1 1150 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.19, 1.31]
2 Symptomatic DVT: LMWH vs
aspirin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Symptomatic DVT: LMWH vs
warfarin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Symptomatic DVT: vitamin K
antagonists vs placebo
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Symptomatic DVT: warfarin vs
aspirin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 5. Anticoagulants versus control: asymptomatic VTE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Asymptomatic VTE: LMWH vs
placebo
2 1682 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.27, 1.54]
1.1 Certoparine 1 532 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.17, 1.90]
1.2 Nadroparin 1 1150 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.21, 2.62]
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Comparison 6. Anticoagulants versus control: overall VTE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall VTE: LMWH vs
placebo
2 1682 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.34, 0.88]
1.1 Certoparine 1 532 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.27, 1.06]
1.2 Nadroparin 1 1150 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.29, 1.08]
Comparison 7. Anticoagulants versus control: minor bleeding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Minor bleeding: LMWH vs
placebo
4 1746 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.76, 1.42]
1.1 Dalteparine 3 596 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.63, 2.04]
1.2 Nadroparin 1 1150 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.69, 1.45]
2 Minor bleeding: LMWH vs
aspirin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Minor bleeding: LMWH vs
warfarin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Minor bleeding: vitamin K
antagonists vs placebo
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Minor bleeding: warfarin vs
aspirin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 8. Anticoagulants versus control: one-year mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 One-year mortality: LMWH vs
placebo
4 1848 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.92, 1.16]
1.1 Dalteparine 3 698 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.86, 1.26]
1.2 Nadroparin 1 1150 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.92, 1.23]
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Comparison 9. Anticoagulants versus control: symptomatic arterial thromboembolism
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic arterial
thromboembolism: LMWH vs
placebo
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Nadroparin 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Symptomatic arterial
thromboembolism: LMWH vs
aspirin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Symptomatic arterial
thromboembolism: LMWH vs
warfarin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Symptomatic arterial
thromboembolism: vitamin K
antagonists vs placebo
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Symptomatic arterial
thromboembolism: warfarin vs
aspirin
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 10. Anticoagulants versus control: superficial thrombophlebitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Superficial thrombophlebitis:
LMWH vs placebo
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Nadroparin 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 11. Anticoagulants versus control: serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events: LMWH
vs placebo
3 1372 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.54, 2.69]
1.1 Dalteparine 2 222 Risk Ratio (M-H, Random, 95% CI) 2.50 [0.65, 9.64]
1.2 Nadroparin 1 1150 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.68, 1.17]
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Comparison 12. Anticoagulants versus control: symptomatic VTE in lung cancer
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic VTE in lung
cancer: LMWH vs control
3 895 Odds Ratio (M-H, Fixed, 95% CI) 0.54 [0.27, 1.09]
Comparison 13. Anticoagulants versus control: major bleeding in lung cancer
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Major bleeding in lung cancer:
LMWH vs control
2 825 Odds Ratio (M-H, Fixed, 95% CI) 1.73 [0.65, 4.57]
Analysis 1.1. Comparison 1 Anticoagulants versus control: symptomatic VTE, Outcome 1 Symptomatic
VTE: LMWH vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 1 Anticoagulants versus control: symptomatic VTE
Outcome: 1 Symptomatic VTE: LMWH vs placebo
Study or subgroup LMWH placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dalteparine
Altinbas 2004 0/42 1/42 1.6 % 0.33 [ 0.01, 7.96 ]
Kakkar 2004 4/190 5/184 9.7 % 0.77 [ 0.21, 2.84 ]
Perry 2010 11/99 13/87 29.2 % 0.74 [ 0.35, 1.57 ]
Sideras 2006 4/68 5/70 10.1 % 0.82 [ 0.23, 2.94 ]
Subtotal (95% CI) 399 383 50.6 % 0.75 [ 0.42, 1.32 ]
Total events: 19 (LMWH), 24 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
2 Certoparine
Haas 2005 8/268 15/264 23.2 % 0.53 [ 0.23, 1.22 ]
0.01 0.1 1 10 100
Favours LMWH Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup LMWH placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 268 264 23.2 % 0.53 [ 0.23, 1.22 ]
Total events: 8 (LMWH), 15 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
3 Nadroparin
Agnelli 2009 12/769 12/381 26.2 % 0.50 [ 0.22, 1.09 ]
Subtotal (95% CI) 769 381 26.2 % 0.50 [ 0.22, 1.09 ]
Total events: 12 (LMWH), 12 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
Total (95% CI) 1436 1028 100.0 % 0.62 [ 0.41, 0.93 ]
Total events: 39 (LMWH), 51 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 5 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Chi2 = 0.86, df = 2 (P = 0.65), I2 =0.0%
0.01 0.1 1 10 100
Favours LMWH Favours placebo
Analysis 1.2. Comparison 1 Anticoagulants versus control: symptomatic VTE, Outcome 2 Symptomatic
VTE: LMWH vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 1 Anticoagulants versus control: symptomatic VTE
Outcome: 2 Symptomatic VTE: LMWH vs aspirin
Study or subgroup LMWH aspirin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 6/219 12/220 0.50 [ 0.19, 1.31 ]
0.01 0.1 1 10 100
Favours LMWH Favours aspirin
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Analysis 1.3. Comparison 1 Anticoagulants versus control: symptomatic VTE, Outcome 3 Symptomatic
VTE: LMWH vs warfarin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 1 Anticoagulants versus control: symptomatic VTE
Outcome: 3 Symptomatic VTE: LMWH vs warfarin
Study or subgroup LMWH warfarin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 6/219 18/220 0.33 [ 0.14, 0.83 ]
0.01 0.1 1 10 100
Favours LMWH Favours warfarin
Analysis 1.4. Comparison 1 Anticoagulants versus control: symptomatic VTE, Outcome 4 Symptomatic
VTE: vitamin K antagonists vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 1 Anticoagulants versus control: symptomatic VTE
Outcome: 4 Symptomatic VTE: vitamin K antagonists vs placebo
Study or subgroup VKA placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Levine 1994 1/152 7/159 0.15 [ 0.02, 1.20 ]
0.01 0.1 1 10 100
Favours VKA Favours placebo
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Analysis 1.5. Comparison 1 Anticoagulants versus control: symptomatic VTE, Outcome 5 Symptomatic
VTE: warfarin vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 1 Anticoagulants versus control: symptomatic VTE
Outcome: 5 Symptomatic VTE: warfarin vs aspirin
Study or subgroup warfarin aspirin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 18/220 12/220 1.50 [ 0.74, 3.04 ]
0.01 0.1 1 10 100
Favours warfarin Favours aspirin
Analysis 1.6. Comparison 1 Anticoagulants versus control: symptomatic VTE, Outcome 6 Symptomatic
VTE: antithrombin vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 1 Anticoagulants versus control: symptomatic VTE
Outcome: 6 Symptomatic VTE: antithrombin vs placebo
Study or subgroup antithrombin placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mitchell 2003 7/25 20/60 0.84 [ 0.41, 1.73 ]
0.01 0.1 1 10 100
Favours antithrombin Favours placebo
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Analysis 2.1. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 1 Major bleeding:
LMWH vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 1 Major bleeding: LMWH vs placebo
Study or subgroup LMWH placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dalteparine
Kakkar 2004 1/190 0/184 6.5 % 2.91 [ 0.12, 70.87 ]
Perry 2010 5/99 1/87 13.9 % 4.39 [ 0.52, 36.89 ]
Sideras 2006 2/68 5/70 23.0 % 0.41 [ 0.08, 2.05 ]
Subtotal (95% CI) 357 341 43.3 % 1.38 [ 0.26, 7.29 ]
Total events: 8 (LMWH), 6 (placebo)
Heterogeneity: Tau2 = 0.92; Chi2 = 3.45, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 0.38 (P = 0.70)
2 Certoparine
Haas 2005 10/273 6/273 48.9 % 1.67 [ 0.61, 4.52 ]
Subtotal (95% CI) 273 273 48.9 % 1.67 [ 0.61, 4.52 ]
Total events: 10 (LMWH), 6 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
3 Nadroparin
Agnelli 2009 5/769 0/381 7.8 % 5.46 [ 0.30, 98.43 ]
Subtotal (95% CI) 769 381 7.8 % 5.46 [ 0.30, 98.43 ]
Total events: 5 (LMWH), 0 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 1399 995 100.0 % 1.57 [ 0.69, 3.60 ]
Total events: 23 (LMWH), 12 (placebo)
Heterogeneity: Tau2 = 0.11; Chi2 = 4.47, df = 4 (P = 0.35); I2 =10%
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Chi2 = 0.68, df = 2 (P = 0.71), I2 =0.0%
0.01 0.1 1 10 100
Favours LMWH Favours placebo
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Analysis 2.2. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 2 Major bleeding:
LMWH vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 2 Major bleeding: LMWH vs aspirin
Study or subgroup LMWH aspirin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 0/219 3/220 0.14 [ 0.01, 2.76 ]
0.01 0.1 1 10 100
Favours LMWH Favours aspirin
Analysis 2.3. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 3 Major bleeding:
LMWH vs warfarin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 3 Major bleeding: LMWH vs warfarin
Study or subgroup LMWH warfarin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 0/220 0/220 0.0 [ 0.0, 0.0 ]
0.01 0.1 1 10 100
Favours LMWH Favours warfarin
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Analysis 2.4. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 4 Major bleeding:
vitamin K antagonists vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 4 Major bleeding: vitamin K antagonists vs placebo
Study or subgroup VKA placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Levine 1994 1/152 2/159 0.52 [ 0.05, 5.71 ]
0.01 0.1 1 10 100
Favours VKA Favours placebo
Analysis 2.5. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 5 Major bleeding:
warfarin vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 5 Major bleeding: warfarin vs aspirin
Study or subgroup warfarin aspirin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 0/220 3/220 0.14 [ 0.01, 2.75 ]
0.01 0.1 1 10 100
Favours warfarin Favours aspirin
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Analysis 2.6. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 6 Major bleeding:
antithrombin vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 6 Major bleeding: antithrombin vs placebo
Study or subgroup antithrombin placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mitchell 2003 0/25 1/60 0.78 [ 0.03, 18.57 ]
0.01 0.1 1 10 100
Favours antithrombin Favours placebo
Analysis 3.1. Comparison 3 Anticoagulants versus control: symptomatic PE, Outcome 1 Symptomatic PE:
LMWH vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 3 Anticoagulants versus control: symptomatic PE
Outcome: 1 Symptomatic PE: LMWH vs placebo
Study or subgroup LMWH placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dalteparin
Kakkar 2004 2/190 0/184 13.1 % 4.84 [ 0.23, 100.20 ]
Perry 2010 2/99 4/87 41.5 % 0.44 [ 0.08, 2.34 ]
Subtotal (95% CI) 289 271 54.6 % 1.04 [ 0.11, 10.25 ]
Total events: 4 (LMWH), 4 (placebo)
Heterogeneity: Tau2 = 1.40; Chi2 = 1.90, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.03 (P = 0.97)
2 Nadroparin
Agnelli 2009 3/769 3/381 45.4 % 0.50 [ 0.10, 2.44 ]
Subtotal (95% CI) 769 381 45.4 % 0.50 [ 0.10, 2.44 ]
Total events: 3 (LMWH), 3 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
0.01 0.1 1 10 100
Favours LMWH Favours placebo
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(. . . Continued)
Study or subgroup LMWH placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 1058 652 100.0 % 0.63 [ 0.21, 1.91 ]
Total events: 7 (LMWH), 7 (placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.07, df = 2 (P = 0.36); I2 =3%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
0.01 0.1 1 10 100
Favours LMWH Favours placebo
Analysis 3.2. Comparison 3 Anticoagulants versus control: symptomatic PE, Outcome 2 Symptomatic PE:
LMWH vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 3 Anticoagulants versus control: symptomatic PE
Outcome: 2 Symptomatic PE: LMWH vs aspirin
Study or subgroup LMWH aspirin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 0/219 4/220 0.11 [ 0.01, 2.06 ]
0.01 0.1 1 10 100
Favours LMWH Favours aspirin
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Analysis 3.3. Comparison 3 Anticoagulants versus control: symptomatic PE, Outcome 3 Symptomatic PE:
LMWH vs warfarin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 3 Anticoagulants versus control: symptomatic PE
Outcome: 3 Symptomatic PE: LMWH vs warfarin
Study or subgroup LMWH warfarin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 0/219 4/220 0.11 [ 0.01, 2.06 ]
0.01 0.1 1 10 100
Favours LMWH Favours warfarin
Analysis 3.4. Comparison 3 Anticoagulants versus control: symptomatic PE, Outcome 4 Symptomatic PE:
vitamin K antagonists vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 3 Anticoagulants versus control: symptomatic PE
Outcome: 4 Symptomatic PE: vitamin K antagonists vs placebo
Study or subgroup VKA placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Levine 1994 1/152 1/159 1.05 [ 0.07, 16.58 ]
0.01 0.1 1 10 100
Favours VKA Favours placebo
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Analysis 3.5. Comparison 3 Anticoagulants versus control: symptomatic PE, Outcome 5 Symptomatic PE:
warfarin vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 3 Anticoagulants versus control: symptomatic PE
Outcome: 5 Symptomatic PE: warfarin vs aspirin
Study or subgroup warfarin aspirin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 4/220 4/220 1.00 [ 0.25, 3.95 ]
0.01 0.1 1 10 100
Favours warfarin Favours aspirin
Analysis 4.1. Comparison 4 Anticoagulants versus control: symptomatic DVT, Outcome 1 Symptomatic
DVT: LMWH vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 4 Anticoagulants versus control: symptomatic DVT
Outcome: 1 Symptomatic DVT: LMWH vs placebo
Study or subgroup LMWH placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dalteparin
Altinbas 2004 0/42 1/42 3.4 % 0.33 [ 0.01, 7.96 ]
Kakkar 2004 1/190 4/184 7.2 % 0.24 [ 0.03, 2.15 ]
Perry 2010 10/99 11/87 52.9 % 0.80 [ 0.36, 1.79 ]
Subtotal (95% CI) 331 313 63.6 % 0.67 [ 0.32, 1.39 ]
Total events: 11 (LMWH), 16 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
2 Nadroparin
Agnelli 2009 8/769 8/381 36.4 % 0.50 [ 0.19, 1.31 ]
Subtotal (95% CI) 769 381 36.4 % 0.50 [ 0.19, 1.31 ]
Total events: 8 (LMWH), 8 (placebo)
0.01 0.1 1 10 100
Favours LMWH Favours placebo
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(. . . Continued)
Study or subgroup LMWH placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Total (95% CI) 1100 694 100.0 % 0.60 [ 0.33, 1.07 ]
Total events: 19 (LMWH), 24 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.44, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
0.01 0.1 1 10 100
Favours LMWH Favours placebo
Analysis 4.2. Comparison 4 Anticoagulants versus control: symptomatic DVT, Outcome 2 Symptomatic
DVT: LMWH vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 4 Anticoagulants versus control: symptomatic DVT
Outcome: 2 Symptomatic DVT: LMWH vs aspirin
Study or subgroup LMWH aspirin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 6/220 8/220 0.75 [ 0.26, 2.13 ]
0.01 0.1 1 10 100
Favours LMWH Favours aspirin
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Analysis 4.3. Comparison 4 Anticoagulants versus control: symptomatic DVT, Outcome 3 Symptomatic
DVT: LMWH vs warfarin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 4 Anticoagulants versus control: symptomatic DVT
Outcome: 3 Symptomatic DVT: LMWH vs warfarin
Study or subgroup LMWH warfarin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 6/219 14/220 0.43 [ 0.17, 1.10 ]
0.01 0.1 1 10 100
Favours LMWH Favours warfarin
Analysis 4.4. Comparison 4 Anticoagulants versus control: symptomatic DVT, Outcome 4 Symptomatic
DVT: vitamin K antagonists vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 4 Anticoagulants versus control: symptomatic DVT
Outcome: 4 Symptomatic DVT: vitamin K antagonists vs placebo
Study or subgroup VKA placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Levine 1994 0/152 6/159 0.08 [ 0.00, 1.42 ]
0.01 0.1 1 10 100
Favours VKA Favours placebo
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Analysis 4.5. Comparison 4 Anticoagulants versus control: symptomatic DVT, Outcome 5 Symptomatic
DVT: warfarin vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 4 Anticoagulants versus control: symptomatic DVT
Outcome: 5 Symptomatic DVT: warfarin vs aspirin
Study or subgroup warfarin aspirin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 14/220 8/220 1.75 [ 0.75, 4.09 ]
0.01 0.1 1 10 100
Favours warfarin Favours aspirin
Analysis 5.1. Comparison 5 Anticoagulants versus control: asymptomatic VTE, Outcome 1 Asymptomatic
VTE: LMWH vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 5 Anticoagulants versus control: asymptomatic VTE
Outcome: 1 Asymptomatic VTE: LMWH vs placebo
Study or subgroup LMWH placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Certoparine
Haas 2005 4/268 7/264 51.7 % 0.56 [ 0.17, 1.90 ]
Subtotal (95% CI) 268 264 51.7 % 0.56 [ 0.17, 1.90 ]
Total events: 4 (LMWH), 7 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
2 Nadroparin
Agnelli 2009 6/769 4/381 48.3 % 0.74 [ 0.21, 2.62 ]
Subtotal (95% CI) 769 381 48.3 % 0.74 [ 0.21, 2.62 ]
Total events: 6 (LMWH), 4 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Total (95% CI) 1037 645 100.0 % 0.64 [ 0.27, 1.54 ]
0.01 0.1 1 10 100
Favours LMWH Favours placebo
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(. . . Continued)
Study or subgroup LMWH placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 10 (LMWH), 11 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.76), I2 =0.0%
0.01 0.1 1 10 100
Favours LMWH Favours placebo
Analysis 6.1. Comparison 6 Anticoagulants versus control: overall VTE, Outcome 1 Overall VTE: LMWH vs
placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 6 Anticoagulants versus control: overall VTE
Outcome: 1 Overall VTE: LMWH vs placebo
Study or subgroup LMWH placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Certoparine
Haas 2005 12/268 22/264 48.5 % 0.54 [ 0.27, 1.06 ]
Subtotal (95% CI) 268 264 48.5 % 0.54 [ 0.27, 1.06 ]
Total events: 12 (LMWH), 22 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.074)
2 Nadroparin
Agnelli 2009 18/769 16/381 51.5 % 0.56 [ 0.29, 1.08 ]
Subtotal (95% CI) 769 381 51.5 % 0.56 [ 0.29, 1.08 ]
Total events: 18 (LMWH), 16 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
Total (95% CI) 1037 645 100.0 % 0.55 [ 0.34, 0.88 ]
Total events: 30 (LMWH), 38 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
0.01 0.1 1 10 100
Favours LMWH Favours placebo
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Analysis 7.1. Comparison 7 Anticoagulants versus control: minor bleeding, Outcome 1 Minor bleeding:
LMWH vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 7 Anticoagulants versus control: minor bleeding
Outcome: 1 Minor bleeding: LMWH vs placebo
Study or subgroup LMWH placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dalteparine
Altinbas 2004 1/42 0/42 1.0 % 3.00 [ 0.13, 71.61 ]
Kakkar 2004 8/190 5/184 8.1 % 1.55 [ 0.52, 4.65 ]
Sideras 2006 12/68 13/70 19.3 % 0.95 [ 0.47, 1.93 ]
Subtotal (95% CI) 300 296 28.3 % 1.14 [ 0.63, 2.04 ]
Total events: 21 (LMWH), 18 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
2 Nadroparin
Agnelli 2009 77/769 38/381 71.7 % 1.00 [ 0.69, 1.45 ]
Subtotal (95% CI) 769 381 71.7 % 1.00 [ 0.69, 1.45 ]
Total events: 77 (LMWH), 38 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 1069 677 100.0 % 1.04 [ 0.76, 1.42 ]
Total events: 98 (LMWH), 56 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.03, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 0.12, df = 1 (P = 0.73), I2 =0.0%
0.01 0.1 1 10 100
Favours LMWH Favours placebo
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Analysis 7.2. Comparison 7 Anticoagulants versus control: minor bleeding, Outcome 2 Minor bleeding:
LMWH vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 7 Anticoagulants versus control: minor bleeding
Outcome: 2 Minor bleeding: LMWH vs aspirin
Study or subgroup LMWH aspirin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 3/219 6/220 0.50 [ 0.13, 1.98 ]
0.01 0.1 1 10 100
Favours LMWH Favours aspirin
Analysis 7.3. Comparison 7 Anticoagulants versus control: minor bleeding, Outcome 3 Minor bleeding:
LMWH vs warfarin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 7 Anticoagulants versus control: minor bleeding
Outcome: 3 Minor bleeding: LMWH vs warfarin
Study or subgroup LMWH warfarin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 3/219 1/220 3.01 [ 0.32, 28.75 ]
0.01 0.1 1 10 100
Favours LMWH Favours warfarin
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Analysis 7.4. Comparison 7 Anticoagulants versus control: minor bleeding, Outcome 4 Minor bleeding:
vitamin K antagonists vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 7 Anticoagulants versus control: minor bleeding
Outcome: 4 Minor bleeding: vitamin K antagonists vs placebo
Study or subgroup VKA placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Levine 1994 7/152 3/159 2.44 [ 0.64, 9.27 ]
0.01 0.1 1 10 100
Favours VKA Favours placebo
Analysis 7.5. Comparison 7 Anticoagulants versus control: minor bleeding, Outcome 5 Minor bleeding:
warfarin vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 7 Anticoagulants versus control: minor bleeding
Outcome: 5 Minor bleeding: warfarin vs aspirin
Study or subgroup warfarin aspirin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 1/220 6/220 0.17 [ 0.02, 1.37 ]
0.01 0.1 1 10 100
Favours warfarin Favours aspirin
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Analysis 8.1. Comparison 8 Anticoagulants versus control: one-year mortality, Outcome 1 One-year
mortality: LMWH vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 8 Anticoagulants versus control: one-year mortality
Outcome: 1 One-year mortality: LMWH vs placebo
Study or subgroup LMWH placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dalteparine
Kakkar 2004 105/190 112/184 32.3 % 0.91 [ 0.76, 1.08 ]
Perry 2010 45/99 32/87 10.0 % 1.24 [ 0.87, 1.75 ]
Sideras 2006 45/68 41/70 16.9 % 1.13 [ 0.87, 1.47 ]
Subtotal (95% CI) 357 341 59.3 % 1.04 [ 0.86, 1.26 ]
Total events: 195 (LMWH), 185 (placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.47, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 0.39 (P = 0.69)
2 Nadroparin
Agnelli 2009 333/769 155/381 40.7 % 1.06 [ 0.92, 1.23 ]
Subtotal (95% CI) 769 381 40.7 % 1.06 [ 0.92, 1.23 ]
Total events: 333 (LMWH), 155 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Total (95% CI) 1126 722 100.0 % 1.04 [ 0.92, 1.16 ]
Total events: 528 (LMWH), 340 (placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.81, df = 3 (P = 0.28); I2 =21%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
0.01 0.1 1 10 100
Favours LMWH Favours placebo
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Analysis 9.1. Comparison 9 Anticoagulants versus control: symptomatic arterial thromboembolism,
Outcome 1 Symptomatic arterial thromboembolism: LMWH vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 9 Anticoagulants versus control: symptomatic arterial thromboembolism
Outcome: 1 Symptomatic arterial thromboembolism: LMWH vs placebo
Study or subgroup LMWH placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Nadroparin
Agnelli 2009 3/769 3/381 0.50 [ 0.10, 2.44 ]
0.01 0.1 1 10 100
Favours LMWH Favours placebo
Analysis 9.2. Comparison 9 Anticoagulants versus control: symptomatic arterial thromboembolism,
Outcome 2 Symptomatic arterial thromboembolism: LMWH vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 9 Anticoagulants versus control: symptomatic arterial thromboembolism
Outcome: 2 Symptomatic arterial thromboembolism: LMWH vs aspirin
Study or subgroup LMWH aspirin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 4/219 2/220 2.01 [ 0.37, 10.86 ]
0.01 0.1 1 10 100
Favours LMWH Favours aspirin
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Analysis 9.3. Comparison 9 Anticoagulants versus control: symptomatic arterial thromboembolism,
Outcome 3 Symptomatic arterial thromboembolism: LMWH vs warfarin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 9 Anticoagulants versus control: symptomatic arterial thromboembolism
Outcome: 3 Symptomatic arterial thromboembolism: LMWH vs warfarin
Study or subgroup LMWH warfarin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 4/219 0/220 9.04 [ 0.49, 166.92 ]
0.01 0.1 1 10 100
Favours LMWH Favours warfarin
Analysis 9.4. Comparison 9 Anticoagulants versus control: symptomatic arterial thromboembolism,
Outcome 4 Symptomatic arterial thromboembolism: vitamin K antagonists vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 9 Anticoagulants versus control: symptomatic arterial thromboembolism
Outcome: 4 Symptomatic arterial thromboembolism: vitamin K antagonists vs placebo
Study or subgroup VKA placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Levine 1994 0/152 0/159 0.0 [ 0.0, 0.0 ]
0.01 0.1 1 10 100
Favours VKA Favours placebo
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Analysis 9.5. Comparison 9 Anticoagulants versus control: symptomatic arterial thromboembolism,
Outcome 5 Symptomatic arterial thromboembolism: warfarin vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 9 Anticoagulants versus control: symptomatic arterial thromboembolism
Outcome: 5 Symptomatic arterial thromboembolism: warfarin vs aspirin
Study or subgroup warfarin aspirin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palumbo 2011 0/220 2/220 0.20 [ 0.01, 4.14 ]
0.01 0.1 1 10 100
Favours warfarin Favours aspirin
Analysis 10.1. Comparison 10 Anticoagulants versus control: superficial thrombophlebitis, Outcome 1
Superficial thrombophlebitis: LMWH vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 10 Anticoagulants versus control: superficial thrombophlebitis
Outcome: 1 Superficial thrombophlebitis: LMWH vs placebo
Study or subgroup LMWH placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Nadroparin
Agnelli 2009 10/769 6/381 0.83 [ 0.30, 2.26 ]
0.01 0.1 1 10 100
Favours LMWH Favours placebo
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Analysis 11.1. Comparison 11 Anticoagulants versus control: serious adverse events, Outcome 1 Serious
adverse events: LMWH vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 11 Anticoagulants versus control: serious adverse events
Outcome: 1 Serious adverse events: LMWH vs placebo
Study or subgroup LMWH placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dalteparine
Altinbas 2004 5/42 1/42 12.2 % 5.00 [ 0.61, 40.99 ]
Sideras 2006 3/68 2/70 16.4 % 1.54 [ 0.27, 8.96 ]
Subtotal (95% CI) 110 112 28.6 % 2.50 [ 0.65, 9.64 ]
Total events: 8 (LMWH), 3 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
2 Nadroparin
Agnelli 2009 121/769 67/381 71.4 % 0.89 [ 0.68, 1.17 ]
Subtotal (95% CI) 769 381 71.4 % 0.89 [ 0.68, 1.17 ]
Total events: 121 (LMWH), 67 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 879 493 100.0 % 1.21 [ 0.54, 2.69 ]
Total events: 129 (LMWH), 70 (placebo)
Heterogeneity: Tau2 = 0.21; Chi2 = 2.88, df = 2 (P = 0.24); I2 =31%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 2.15, df = 1 (P = 0.14), I2 =53%
0.01 0.1 1 10 100
Favours LMWH Favours placebo
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Analysis 12.1. Comparison 12 Anticoagulants versus control: symptomatic VTE in lung cancer, Outcome 1
Symptomatic VTE in lung cancer: LMWH vs control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 12 Anticoagulants versus control: symptomatic VTE in lung cancer
Outcome: 1 Symptomatic VTE in lung cancer: LMWH vs control
Study or subgroup LMWH control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Agnelli 2009 7/199 4/80 25.4 % 0.69 [ 0.20, 2.43 ]
Altinbas 2004 0/42 1/42 6.8 % 0.33 [ 0.01, 8.22 ]
Haas 2005 8/268 15/264 67.7 % 0.51 [ 0.21, 1.23 ]
Total (95% CI) 509 386 100.0 % 0.54 [ 0.27, 1.09 ]
Total events: 15 (LMWH), 20 (control)
Heterogeneity: Chi2 = 0.26, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours control
Analysis 13.1. Comparison 13 Anticoagulants versus control: major bleeding in lung cancer, Outcome 1
Major bleeding in lung cancer: LMWH vs control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 13 Anticoagulants versus control: major bleeding in lung cancer
Outcome: 1 Major bleeding in lung cancer: LMWH vs control
Study or subgroup LMWH control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Agnelli 2009 2/199 0/80 10.8 % 2.04 [ 0.10, 42.92 ]
Haas 2005 10/273 6/273 89.2 % 1.69 [ 0.61, 4.72 ]
Total (95% CI) 472 353 100.0 % 1.73 [ 0.65, 4.57 ]
Total events: 12 (LMWH), 6 (control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours control
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A D D I T I O N A L T A B L E S
Table 1. Results of stratified analyses on major bleeding
Variable N of trials N of patients
(LMWH)
N of patients
(control)
RR (95% CI) Heterogeneity
I2 (%)
P for interaction
All trials 5 1399 995 1.57 (69 to 3.60) 10%
Allocation con-
cealment
0.24
Adequate 3 1058 652 4.25 (0.94 to 19.
24)
0%
Inadequate or
unclear
2 341 343 0.96 (0.25 to 3.
66)
52%
Blinding of pa-
tients
0.17
Double-blind 4 1331 925 2.21 (0.96 to 5.
09)
0%
Inadequate or
unclear blinding
1 68 70 0.41 (0.08 to 2.
05)
N/A
Intention-to-
treat analysis
0.41
Yes 1 99 87 4.39 (0.52 to 36.
89)
No or unclear 4 1300 925 1.33 (0.54 to 3.
28)
11.5
Definition of
bleeding
0.24
Standard 3 1058 652 4.25 (0.94 to 19.
24)
0%
Alternative or
unclear
2 341 343 0.96 (0.25 to 3.
66)
52.4%
Age 0.17
mean > 65 years 4 1331 925 2.21 (0.96 to 5.
09)
0%
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Table 1. Results of stratified analyses on major bleeding (Continued)
mean < 65 years 1 68 70 0.41 (0.08 to 2.
05)
N/A
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Thrombosis, this term only 1077
#2 MeSH descriptor Thromboembolism, this term only 974
#3 MeSH descriptor Venous Thromboembolism, this term only 159
#4 MeSH descriptor Venous Thrombosis, this term only 924
#5 (thromboprophyla* or thrombus* or thrombotic* or throm-
bolic* or thromboemboli* or thrombos* or embol*):ti,ab,kw
10726
#6 MeSH descriptor Pulmonary Embolism explode all trees 818
#7 (PE or DVT or VTE):ti,ab,kw 1961
#8 ((deep near (vein* or ven*) near thromb*) or “blood flow stasis”
or “vein stasis” or “venous stasis” or “blood clot”):ti,ab,kw
2767
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8) 11955
#10 MeSH descriptor Neoplasms explode all trees 42654
#11 (malignan* or neoplas* or cancer* or carcinoma* or adenocar-
cinoma* or tumour* or tumor* or glio* or leukemia or che-
motherapy or myeloma or oncology):ti,ab,kw
79055
#12 (#10 OR #11) 80801
#13 (#9 AND #12) 1328
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Appendix 2. Abbreviations and scientific terms
Abbreviation Scientific description Lay description
Anticoagulation therapy Blood thinning therapy
GES Graduated elastic stockings Graduated elastic stockings are special socks that improve blood flow in the
leg veins and prevent blood from pooling in the legs
Incidence Number of newly diagnosed diseases, in this review cases of VTE
IPC Intermittent pneumatic compression A mechanical intervention using an air pump and inflatable leggings to
provide pulsing pressure that pushes blood through the veins
Primary prophylaxis Primary protective treatment aiming at the prevention of disease develop-
ment
Tromboprophylaxis Treatment to prevent the development of blood clots
VTE Venous thromboembolism Blood clots
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol we aimed to combine continuous data from quality of life instruments applying, where appropriate, standard inverse-
variance random-effects model meta-analysis (DerSimonian 1986). As none of the included studies reported quality of life data, this
was omitted.
In the protocol we planned to explore between trial heterogeneity by stratifying the main outcomes for the following clinical trial
characteristics, where relevant: age (below 65 years versus above 65 years); type of cancer, stage of cancer (metastatic versus non
metastatic); type of major bleeding (according to definition versus unclear or different definition); concealment of allocation (adequate
versus inadequate or unclear); blinding (adequate versus inadequate or unclear); analysis in accordance with the intention-to-treat
principle (yes versus no or unclear); trial size; and differences in the use of co-interventions in the trial groups. We planned to use
univariate random-effects meta-regression models (Thompson 1999) to determine whether treatment effects were affected by these
factors and by three continuous variables at trial level: dosage of intervention, treatment duration and length of follow up. Due to the
absence of heterogeneity for the primary efficacy outcome, symptomatic VTE, no such stratified analysis was performed.
Regarding major bleeding, there was not enough contrast to explore the effect of the following trial characteristics: type of cancer, stage
of cancer (metastatic versus non metastatic) and differences in the use of co-interventions in the trials groups. Moreover, the number
of studies was too limited to allow an analysis for dosage of intervention, treatment duration and length of follow up.
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